TFS HealthScience Acquires Appletree CI Group, Expanding Presence in Ophthalmology

Contract research organization TFS HealthScience announced it has acquired Appletree CI Group, a CRO and global regulatory affairs service provider.

Terms of the deal were not disclosed.

The deal enhances TFS HealthScience's presence in the fields of ophthalmology, dermatology, medical devices, and pediatric studies, simultaneously expanding geographic reach for clients. 

"We are proud to partner with Appletree as we continue to provide our clients with in-depth, comprehensive knowledge and therapeutic expertise, particularly in the field of ophthalmology," said CEO of TFS HealthScience, Bassem Saleh. "This acquisition, and others in the pipeline, are a clear indicator of the growth and success of TFS. The partnership with Appletree will have a measurable impact on better treatments for patients and company growth, establishing a new presence in Switzerland and additional presence in Poland, Belgium, Hungary, and the U.K."

In a news release, TFS HealthScience stated the acquisition of Appletree will complement the company's mission to be a market leader in ophthalmology research. 

"Today is a significant milestone for our company as we finalize our first acquisition in Ophthalmology, establishing clear leadership in a niche industry where expertise is highly valued, as clinical trials and strategy for ophthalmology indications are held to specific rules and regulations," said VP of TFS HealthScience's Ophthalmology Business Unit, Marcia Swank.   

The two companies will now offer clients complimentary and expanded service offerings, including a specialized therapeutic focus in ophthalmology with an increased global footprint.  

Appletree CI Group was founded in 2013 following the merger of Clinical Investigations and Appletree AG.